{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T16:14:02Z","timestamp":1791562442374,"version":"4.3.4"},"reference-count":115,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T00:00:00Z","timestamp":1742515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T00:00:00Z","timestamp":1742515200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["ICMx"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>While a dysregulated immune response is at the center of the sepsis definition, standard care is still solely focussed on prompt administration of antimicrobial therapy, source control, resuscitation and organ supportive therapies. Extracorporeal blood purification therapies, such as haemoadsorption, have been proposed as a possible adjunctive therapy to standard care in sepsis. These adsorption devices aim to rebalance the dysregulated immune response by removal of excessive amounts of circulating inflammatory mediators, including cytokines and endotoxins. Thus far, the effects of haemoadsorption on clinical outcomes have been insufficiently studied and although its routine use is not justified based on the current evidence, multiple centers use these devices in patients with severe septic shock. This narrative review describes the most well-studied adsorption devices as well as a novel selective adsorption device called the \u2018IL-6-Sieve\u2019, including in vitro data showing its capturing potential. Finally, it addresses important considerations for future trials on haemoadsorption in septic patients.<\/jats:p>","DOI":"10.1186\/s40635-025-00740-0","type":"journal-article","created":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T16:03:59Z","timestamp":1742573039000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Haemoadsorption to remove inflammatory mediators in sepsis: past, present, and future"],"prefix":"10.1186","volume":"13","author":[{"given":"Nicole J. B.","family":"Waalders","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthijs","family":"Kox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1104-4303","authenticated-orcid":false,"given":"Peter","family":"Pickkers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,21]]},"reference":[{"key":"740_CR1","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/s0140-6736(19)32989-7","volume":"395","author":"KE Rudd","year":"2020","unstructured":"Rudd KE, Johnson SC, Agesa KM et al (2020) Global, regional, and national sepsis incidence and mortality, 1990\u20132017: analysis for the Global Burden of Disease Study. Lancet 395:200\u2013211. https:\/\/doi.org\/10.1016\/s0140-6736(19)32989-7","journal-title":"Lancet"},{"key":"740_CR2","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1038\/nri3552","volume":"13","author":"RS Hotchkiss","year":"2013","unstructured":"Hotchkiss RS, Monneret G, Payen D (2013) Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol 13:862\u2013874. https:\/\/doi.org\/10.1038\/nri3552","journal-title":"Nat Rev Immunol"},{"key":"740_CR3","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1016\/j.immuni.2021.10.012","volume":"54","author":"T van der Poll","year":"2021","unstructured":"van der Poll T, Shankar-Hari M, Wiersinga WJ (2021) The immunology of sepsis. Immunity 54:2450\u20132464. https:\/\/doi.org\/10.1016\/j.immuni.2021.10.012","journal-title":"Immunity"},{"key":"740_CR4","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/nri.2017.36","volume":"17","author":"T van der Poll","year":"2017","unstructured":"van der Poll T, van de Veerdonk FL, Scicluna BP et al (2017) The immunopathology of sepsis and potential therapeutic targets. Nat Rev Immunol 17:407\u2013420. https:\/\/doi.org\/10.1038\/nri.2017.36","journal-title":"Nat Rev Immunol"},{"key":"740_CR5","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/cc9411","volume":"15","author":"T Rimmel\u00e9","year":"2011","unstructured":"Rimmel\u00e9 T, Kellum JA (2011) Clinical review: blood purification for sepsis. Crit Care 15:205. https:\/\/doi.org\/10.1186\/cc9411","journal-title":"Crit Care"},{"key":"740_CR6","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/cc1889","volume":"7","author":"R Venkataraman","year":"2003","unstructured":"Venkataraman R, Subramanian S, Kellum JA (2003) Clinical review: extracorporeal blood purification in severe sepsis. Crit Care 7:139\u2013145. https:\/\/doi.org\/10.1186\/cc1889","journal-title":"Crit Care"},{"key":"740_CR7","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1159\/000492379","volume":"46","author":"A Bonavia","year":"2018","unstructured":"Bonavia A, Groff A, Karamchandani K et al (2018) Clinical utility of extracorporeal cytokine hemoadsorption therapy: a literature review. Blood Purif 46:337\u2013349. https:\/\/doi.org\/10.1159\/000492379","journal-title":"Blood Purif"},{"key":"740_CR8","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1186\/s13054-016-1456-5","volume":"20","author":"G Villa","year":"2016","unstructured":"Villa G, Neri M, Bellomo R et al (2016) Nomenclature for renal replacement therapy and blood purification techniques in critically ill patients: practical applications. Crit Care 20:283. https:\/\/doi.org\/10.1186\/s13054-016-1456-5","journal-title":"Crit Care"},{"key":"740_CR9","doi-asserted-by":"publisher","DOI":"10.1159\/000533468","author":"M Ostermann","year":"2023","unstructured":"Ostermann M, Ankawi G, Cantaluppi V et al (2023) Nomenclature of extracorporeal blood purification therapies for acute indications: the nomenclature standardization conference. Blood Purif. https:\/\/doi.org\/10.1159\/000533468","journal-title":"Blood Purif"},{"key":"740_CR10","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1159\/000074937","volume":"22","author":"C Ronco","year":"2004","unstructured":"Ronco C, Bonello M, Bordoni V et al (2004) Extracorporeal therapies in non-renal disease: treatment of sepsis and the peak concentration hypothesis. Blood Purif 22:164\u2013174. https:\/\/doi.org\/10.1159\/000074937","journal-title":"Blood Purif"},{"key":"740_CR11","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1046\/j.1525-1594.2003.07289.x","volume":"27","author":"C Ronco","year":"2003","unstructured":"Ronco C, Tetta C, Mariano F et al (2003) Interpreting the mechanisms of continuous renal replacement therapy in sepsis: the peak concentration hypothesis. Artif Organs 27:792\u2013801. https:\/\/doi.org\/10.1046\/j.1525-1594.2003.07289.x","journal-title":"Artif Organs"},{"key":"740_CR12","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1097\/01.ccm.0000115262.31804.46","volume":"32","author":"PM Honor\u00e9","year":"2004","unstructured":"Honor\u00e9 PM, Matson JR (2004) Extracorporeal removal for sepsis: acting at the tissue level\u2013the beginning of a new era for this treatment modality in septic shock. Crit Care Med 32:896\u2013897. https:\/\/doi.org\/10.1097\/01.ccm.0000115262.31804.46","journal-title":"Crit Care Med"},{"key":"740_CR13","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1159\/000313773","volume":"165","author":"Z Peng","year":"2010","unstructured":"Peng Z, Singbartl K, Simon P et al (2010) Blood purification in sepsis: a new paradigm. Contrib Nephrol 165:322\u2013328. https:\/\/doi.org\/10.1159\/000313773","journal-title":"Contrib Nephrol"},{"key":"740_CR14","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1097\/00003246-200206000-00015","volume":"30","author":"C Ronco","year":"2002","unstructured":"Ronco C, Brendolan A, Lonnemann G et al (2002) A pilot study of coupled plasma filtration with adsorption in septic shock. Crit Care Med 30:1250\u20131255. https:\/\/doi.org\/10.1097\/00003246-200206000-00015","journal-title":"Crit Care Med"},{"key":"740_CR15","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1097\/00003246-200107000-00021","volume":"29","author":"EF Yekebas","year":"2001","unstructured":"Yekebas EF, Eisenberger CF, Ohnesorge H et al (2001) Attenuation of sepsis-related immunoparalysis by continuous veno-venous hemofiltration in experimental porcine pancreatitis. Crit Care Med 29:1423\u20131430. https:\/\/doi.org\/10.1097\/00003246-200107000-00021","journal-title":"Crit Care Med"},{"key":"740_CR16","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1097\/ALN.0b013e318256f0c0","volume":"116","author":"T Rimmel\u00e9","year":"2012","unstructured":"Rimmel\u00e9 T, Kellum JA (2012) High-volume hemofiltration in the intensive care unit: a blood purification therapy. Anesthesiology 116:1377\u20131387. https:\/\/doi.org\/10.1097\/ALN.0b013e318256f0c0","journal-title":"Anesthesiology"},{"key":"740_CR17","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1177\/039139880502800803","volume":"28","author":"JV Di Carlo","year":"2005","unstructured":"Di Carlo JV, Alexander SR (2005) Hemofiltration for cytokine-driven illnesses: the mediator delivery hypothesis. Int J Artif Organs 28:777\u2013786. https:\/\/doi.org\/10.1177\/039139880502800803","journal-title":"Int J Artif Organs"},{"key":"740_CR18","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1038\/ki.2008.462","volume":"74","author":"WJ Holubek","year":"2008","unstructured":"Holubek WJ, Hoffman RS, Goldfarb DS et al (2008) Use of hemodialysis and hemoperfusion in poisoned patients. Kidney Int 74:1327\u20131334. https:\/\/doi.org\/10.1038\/ki.2008.462","journal-title":"Kidney Int"},{"key":"740_CR19","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1053\/j.ajkd.2006.04.080","volume":"48","author":"AS Shalkham","year":"2006","unstructured":"Shalkham AS, Kirrane BM, Hoffman RS et al (2006) The availability and use of charcoal hemoperfusion in the treatment of poisoned patients. Am J Kidney Dis 48:239\u2013241. https:\/\/doi.org\/10.1053\/j.ajkd.2006.04.080","journal-title":"Am J Kidney Dis"},{"key":"740_CR20","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1159\/000067860","volume":"21","author":"JF Winchester","year":"2003","unstructured":"Winchester JF, Kellum JA, Ronco C et al (2003) Sorbents in acute renal failure and the systemic inflammatory response syndrome. Blood Purif 21:79\u201384. https:\/\/doi.org\/10.1159\/000067860","journal-title":"Blood Purif"},{"key":"740_CR21","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s13054-022-04009-w","volume":"26","author":"C Ronco","year":"2022","unstructured":"Ronco C, Bellomo R (2022) Hemoperfusion: technical aspects and state of the art. Crit Care 26:135. https:\/\/doi.org\/10.1186\/s13054-022-04009-w","journal-title":"Crit Care"},{"key":"740_CR22","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-022-06810-1","author":"Z Ricci","year":"2022","unstructured":"Ricci Z, Romagnoli S, Reis T et al (2022) Hemoperfusion in the intensive care unit. Intensive Care Med. https:\/\/doi.org\/10.1007\/s00134-022-06810-1","journal-title":"Intensive Care Med"},{"key":"740_CR23","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1046\/j.1526-0968.2003.00005.x","volume":"7","author":"H Shoji","year":"2003","unstructured":"Shoji H (2003) Extracorporeal endotoxin removal for the treatment of sepsis: endotoxin adsorption cartridge (Toraymyxin). Ther Apher Dial 7:108\u2013114. https:\/\/doi.org\/10.1046\/j.1526-0968.2003.00005.x","journal-title":"Ther Apher Dial"},{"key":"740_CR24","first-page":"M790","volume":"39","author":"T Sato","year":"1993","unstructured":"Sato T, Orlowski JP, Zborowski M (1993) Experimental study of extracorporeal perfusion for septic shock. Asaio j 39:M790\u2013M793","journal-title":"Asaio j"},{"key":"740_CR25","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s40635-018-0177-2","volume":"6","author":"B Malard","year":"2018","unstructured":"Malard B, Lambert C, Kellum JA (2018) In vitro comparison of the adsorption of inflammatory mediators by blood purification devices. Intensive Care Med Exp 6:12. https:\/\/doi.org\/10.1186\/s40635-018-0177-2","journal-title":"Intensive Care Med Exp"},{"key":"740_CR26","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1001\/jama.2009.856","volume":"301","author":"DN Cruz","year":"2009","unstructured":"Cruz DN, Antonelli M, Fumagalli R et al (2009) Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA 301:2445\u20132452. https:\/\/doi.org\/10.1001\/jama.2009.856","journal-title":"JAMA"},{"key":"740_CR27","doi-asserted-by":"publisher","unstructured":"Vincent JL (2009) Polymyxin B hemoperfusion and mortality in abdominal septic shock. Jama 302:1968; author reply 9\u201370. https:\/\/doi.org\/10.1001\/jama.2009.1606.","DOI":"10.1001\/jama.2009.1606"},{"key":"740_CR28","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s13613-016-0178-9","volume":"6","author":"SL Cutuli","year":"2016","unstructured":"Cutuli SL, Artigas A, Fumagalli R et al (2016) Polymyxin-B hemoperfusion in septic patients: analysis of a multicenter registry. Ann Intensive Care 6:77. https:\/\/doi.org\/10.1186\/s13613-016-0178-9","journal-title":"Ann Intensive Care"},{"key":"740_CR29","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s13054-017-1712-3","volume":"21","author":"Y Nakamura","year":"2017","unstructured":"Nakamura Y, Kitamura T, Kiyomi F et al (2017) Potential survival benefit of polymyxin B hemoperfusion in patients with septic shock: a propensity-matched cohort study. Crit Care 21:134. https:\/\/doi.org\/10.1186\/s13054-017-1712-3","journal-title":"Crit Care"},{"key":"740_CR30","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1007\/s00134-015-3751-z","volume":"41","author":"DM Payen","year":"2015","unstructured":"Payen DM, Guilhot J, Launey Y et al (2015) Early use of polymyxin B hemoperfusion in patients with septic shock due to peritonitis: a multicenter randomized control trial. Intensive Care Med 41:975\u2013984. https:\/\/doi.org\/10.1007\/s00134-015-3751-z","journal-title":"Intensive Care Med"},{"key":"740_CR31","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1001\/jama.2018.14618","volume":"320","author":"RP Dellinger","year":"2018","unstructured":"Dellinger RP, Bagshaw SM, Antonelli M et al (2018) Effect of targeted polymyxin B hemoperfusion on 28-day mortality in patients with septic shock and elevated endotoxin level: the EUPHRATES randomized clinical trial. JAMA 320:1455\u20131463. https:\/\/doi.org\/10.1001\/jama.2018.14618","journal-title":"JAMA"},{"key":"740_CR32","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1186\/s13054-018-2077-y","volume":"22","author":"N Srisawat","year":"2018","unstructured":"Srisawat N, Tungsanga S, Lumlertgul N et al (2018) The effect of polymyxin B hemoperfusion on modulation of human leukocyte antigen DR in severe sepsis patients. Crit Care 22:279. https:\/\/doi.org\/10.1186\/s13054-018-2077-y","journal-title":"Crit Care"},{"key":"740_CR33","doi-asserted-by":"publisher","first-page":"e858","DOI":"10.1097\/ccm.0000000000002362","volume":"45","author":"T Chang","year":"2017","unstructured":"Chang T, Tu YK, Lee CT et al (2017) Effects of polymyxin B hemoperfusion on mortality in patients with severe sepsis and septic shock: a systemic review, meta-analysis update, and disease severity subgroup meta-analysis. Crit Care Med 45:e858\u2013e864. https:\/\/doi.org\/10.1097\/ccm.0000000000002362","journal-title":"Crit Care Med"},{"key":"740_CR34","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1159\/000510982","volume":"50","author":"TAC Snow","year":"2021","unstructured":"Snow TAC, Littlewood S, Corredor C et al (2021) Effect of extracorporeal blood purification on mortality in sepsis: a meta-analysis and trial sequential analysis. Blood Purif 50:462\u2013472. https:\/\/doi.org\/10.1159\/000510982","journal-title":"Blood Purif"},{"key":"740_CR35","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s00134-017-5004-9","volume":"44","author":"T Fujii","year":"2018","unstructured":"Fujii T, Ganeko R, Kataoka Y et al (2018) Polymyxin B-immobilized hemoperfusion and mortality in critically ill adult patients with sepsis\/septic shock: a systematic review with meta-analysis and trial sequential analysis. Intensive Care Med 44:167\u2013178. https:\/\/doi.org\/10.1007\/s00134-017-5004-9","journal-title":"Intensive Care Med"},{"key":"740_CR36","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.jcrc.2020.09.007","volume":"63","author":"X Li","year":"2021","unstructured":"Li X, Liu C, Mao Z et al (2021) Effectiveness of polymyxin B-immobilized hemoperfusion against sepsis and septic shock: a systematic review and meta-analysis. J Crit Care 63:187\u2013195. https:\/\/doi.org\/10.1016\/j.jcrc.2020.09.007","journal-title":"J Crit Care"},{"key":"740_CR37","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1097\/aln.0000000000002820","volume":"131","author":"A Putzu","year":"2019","unstructured":"Putzu A, Schorer R, Lopez-Delgado JC et al (2019) Blood purification and mortality in sepsis and septic shock: a systematic review and meta-analysis of randomized trials. Anesthesiology 131:580\u2013593. https:\/\/doi.org\/10.1097\/aln.0000000000002820","journal-title":"Anesthesiology"},{"key":"740_CR38","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1007\/s00134-018-5463-7","volume":"44","author":"DJ Klein","year":"2018","unstructured":"Klein DJ, Foster D, Walker PM et al (2018) Polymyxin B hemoperfusion in endotoxemic septic shock patients without extreme endotoxemia: a post hoc analysis of the EUPHRATES trial. Intensive Care Med 44:2205\u20132212. https:\/\/doi.org\/10.1007\/s00134-018-5463-7","journal-title":"Intensive Care Med"},{"key":"740_CR39","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1007\/s00134-018-5481-5","volume":"45","author":"P Pickkers","year":"2019","unstructured":"Pickkers P, Russell JA (2019) Treatment with a polymyxin B filter to capture endotoxin in sepsis patients: is there a signal for therapeutic efficacy? Intensive Care Med 45:282\u2013283. https:\/\/doi.org\/10.1007\/s00134-018-5481-5","journal-title":"Intensive Care Med"},{"key":"740_CR40","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1186\/s13054-023-04717-x","volume":"27","author":"G Tomlinson","year":"2023","unstructured":"Tomlinson G, Al-Khafaji A, Conrad SA et al (2023) Bayesian methods: a potential path forward for sepsis trials. Crit Care 27:432. https:\/\/doi.org\/10.1186\/s13054-023-04717-x","journal-title":"Crit Care"},{"key":"740_CR41","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.colsurfb.2011.09.046","volume":"90","author":"K Shimokawa","year":"2012","unstructured":"Shimokawa K, Takakuwa R, Taya K et al (2012) Adsorption of various antimicrobial agents to endotoxin removal polymyxin-B immobilized fiber (Toraymyxin\u00ae). Colloids Surf B Biointerfaces 90:58\u201361. https:\/\/doi.org\/10.1016\/j.colsurfb.2011.09.046","journal-title":"Colloids Surf B Biointerfaces"},{"key":"740_CR42","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.colsurfb.2012.06.032","volume":"101","author":"K Shimokawa","year":"2013","unstructured":"Shimokawa K, Takakuwa R, Wada Y et al (2013) Adsorption of various antimicrobial agents to endotoxin removal polymyxin-B immobilized fiber (Toraymyxin\u00ae). Part 2: Adsorption of two drugs to Toraymyxin PMX-20R cartridges. Colloids Surf B Biointerfaces 101:350\u2013352. https:\/\/doi.org\/10.1016\/j.colsurfb.2012.06.032","journal-title":"Colloids Surf B Biointerfaces"},{"key":"740_CR43","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jcrc.2019.02.007","volume":"51","author":"W Singhan","year":"2019","unstructured":"Singhan W, Vadcharavivad S, Areepium N et al (2019) The effect of direct hemoperfusion with polymyxin B immobilized cartridge on meropenem in critically ill patients requiring renal support. J Crit Care 51:71\u201376. https:\/\/doi.org\/10.1016\/j.jcrc.2019.02.007","journal-title":"J Crit Care"},{"key":"740_CR44","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1097\/01.ccm.0000114997.39857.69","volume":"32","author":"JA Kellum","year":"2004","unstructured":"Kellum JA, Song M, Venkataraman R (2004) Hemoadsorption removes tumor necrosis factor, interleukin-6, and interleukin-10, reduces nuclear factor-kappaB DNA binding, and improves short-term survival in lethal endotoxemia. Crit Care Med 32:801\u2013805. https:\/\/doi.org\/10.1097\/01.ccm.0000114997.39857.69","journal-title":"Crit Care Med"},{"key":"740_CR45","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1097\/CCM.0b013e318170b9a7","volume":"36","author":"ZY Peng","year":"2008","unstructured":"Peng ZY, Carter MJ, Kellum JA (2008) Effects of hemoadsorption on cytokine removal and short-term survival in septic rats. Crit Care Med 36:1573\u20131577. https:\/\/doi.org\/10.1097\/CCM.0b013e318170b9a7","journal-title":"Crit Care Med"},{"key":"740_CR46","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s13054-023-04391-z","volume":"27","author":"A Jansen","year":"2023","unstructured":"Jansen A, Waalders NJB, van Lier DPT et al (2023) CytoSorb hemoperfusion markedly attenuates circulating cytokine concentrations during systemic inflammation in humans in vivo. Crit Care 27:117. https:\/\/doi.org\/10.1186\/s13054-023-04391-z","journal-title":"Crit Care"},{"key":"740_CR47","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/s13054-024-04995-z","volume":"28","author":"A Jansen","year":"2024","unstructured":"Jansen A, Waalders N, Kox M et al (2024) Desorption in hemoadsorption therapies: a call for more data. Crit Care 28:207. https:\/\/doi.org\/10.1186\/s13054-024-04995-z","journal-title":"Crit Care"},{"key":"740_CR48","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s13054-024-04968-2","volume":"28","author":"A Buhlmann","year":"2024","unstructured":"Buhlmann A, Erlebach R, M\u00fcller M et al (2024) The phenomenon of desorption: What are the best adsorber exchange intervals? Crit Care 28:178. https:\/\/doi.org\/10.1186\/s13054-024-04968-2","journal-title":"Crit Care"},{"key":"740_CR49","doi-asserted-by":"publisher","first-page":"10493","DOI":"10.1038\/s41598-021-89965-z","volume":"11","author":"AG Schneider","year":"2021","unstructured":"Schneider AG, Andr\u00e9 P, Scheier J et al (2021) Pharmacokinetics of anti-infective agents during CytoSorb hemoadsorption. Sci Rep 11:10493. https:\/\/doi.org\/10.1038\/s41598-021-89965-z","journal-title":"Sci Rep"},{"key":"740_CR50","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s40635-020-00313-3","volume":"8","author":"CN Lang","year":"2020","unstructured":"Lang CN, Sommer MJ, Neukamm MA et al (2020) Use of the CytoSorb adsorption device in MDMA intoxication: a first-in-man application and in vitro study. Intensive Care Med Exp 8:21. https:\/\/doi.org\/10.1186\/s40635-020-00313-3","journal-title":"Intensive Care Med Exp"},{"key":"740_CR51","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0187015","volume":"12","author":"D Sch\u00e4dler","year":"2017","unstructured":"Sch\u00e4dler D, Pausch C, Heise D et al (2017) The effect of a novel extracorporeal cytokine hemoadsorption device on IL-6 elimination in septic patients: a randomized controlled trial. PLoS ONE 12:e0187015. https:\/\/doi.org\/10.1371\/journal.pone.0187015","journal-title":"PLoS ONE"},{"key":"740_CR52","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s13613-021-00905-6","volume":"11","author":"C Scharf","year":"2021","unstructured":"Scharf C, Schroeder I, Paal M et al (2021) Can the cytokine adsorber CytoSorb(\u00ae) help to mitigate cytokine storm and reduce mortality in critically ill patients? A propensity score matching analysis. Ann Intensive Care 11:115. https:\/\/doi.org\/10.1186\/s13613-021-00905-6","journal-title":"Ann Intensive Care"},{"key":"740_CR53","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13054-016-1270-0","volume":"20","author":"MH Bernardi","year":"2016","unstructured":"Bernardi MH, Rinoesl H, Dragosits K et al (2016) Effect of hemoadsorption during cardiopulmonary bypass surgery\u2014a blinded, randomized, controlled pilot study using a novel adsorbent. Crit Care 20:96. https:\/\/doi.org\/10.1186\/s13054-016-1270-0","journal-title":"Crit Care"},{"key":"740_CR54","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1097\/ccm.0000000000004847","volume":"49","author":"R van Groenendael","year":"2021","unstructured":"van Groenendael R, Beunders R, Hemelaar P et al (2021) Safety and efficacy of human chorionic gonadotropin hormone-derivative EA-230 in cardiac surgery patients: a randomized double-blind placebo-controlled study. Crit Care Med 49:790\u2013803. https:\/\/doi.org\/10.1097\/ccm.0000000000004847","journal-title":"Crit Care Med"},{"key":"740_CR55","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.jcrc.2018.11.003","volume":"49","author":"F Hawchar","year":"2019","unstructured":"Hawchar F, L\u00e1szl\u00f3 I, \u00d6veges N et al (2019) Extracorporeal cytokine adsorption in septic shock: a proof of concept randomized, controlled pilot study. J Crit Care 49:172\u2013178. https:\/\/doi.org\/10.1016\/j.jcrc.2018.11.003","journal-title":"J Crit Care"},{"key":"740_CR56","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1186\/s13054-023-04492-9","volume":"27","author":"S Becker","year":"2023","unstructured":"Becker S, Lang H, Vollmer Barbosa C et al (2023) Efficacy of CytoSorb\u00ae: a systematic review and meta-analysis. Crit Care 27:215. https:\/\/doi.org\/10.1186\/s13054-023-04492-9","journal-title":"Crit Care"},{"key":"740_CR57","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1111\/aas.14115","volume":"66","author":"M Heymann","year":"2022","unstructured":"Heymann M, Schorer R, Putzu A (2022) Mortality and adverse events of hemoadsorption with CytoSorb\u00ae in critically ill patients: a systematic review and meta-analysis of randomized controlled trials. Acta Anaesthesiol Scand 66:1037\u20131050. https:\/\/doi.org\/10.1111\/aas.14115","journal-title":"Acta Anaesthesiol Scand"},{"key":"740_CR58","doi-asserted-by":"publisher","DOI":"10.1097\/ccm.0000000000006007","author":"M Heymann","year":"2023","unstructured":"Heymann M, Schorer R, Putzu A (2023) The effect of cytosorb on inflammatory markers in critically ill patients: a systematic review and meta-analysis of randomized controlled trials. Crit Care Med. https:\/\/doi.org\/10.1097\/ccm.0000000000006007","journal-title":"Crit Care Med"},{"key":"740_CR59","doi-asserted-by":"publisher","first-page":"e152","DOI":"10.1097\/ccm.0000000000006120","volume":"52","author":"NJB Waalders","year":"2024","unstructured":"Waalders NJB, Jansen A, Pickkers P (2024) Effect of CytoSorb on interleukin-6. Crit Care Med 52:e152\u2013e153. https:\/\/doi.org\/10.1097\/ccm.0000000000006120","journal-title":"Crit Care Med"},{"key":"740_CR60","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/0391398818812601","volume":"42","author":"C K\u00f6nig","year":"2019","unstructured":"K\u00f6nig C, R\u00f6hr AC, Frey OR et al (2019) In vitro removal of anti-infective agents by a novel cytokine adsorbent system. Int J Artif Organs 42:57\u201364. https:\/\/doi.org\/10.1177\/0391398818812601","journal-title":"Int J Artif Organs"},{"key":"740_CR61","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13613-022-01017-5","volume":"12","author":"C Scharf","year":"2022","unstructured":"Scharf C, Weinelt F, Schroeder I et al (2022) Does the cytokine adsorber CytoSorb\u00ae reduce vancomycin exposure in critically ill patients with sepsis or septic shock? a prospective observational study. Ann Intensive Care 12:44. https:\/\/doi.org\/10.1186\/s13613-022-01017-5","journal-title":"Ann Intensive Care"},{"key":"740_CR62","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.athoracsur.2018.12.032","volume":"108","author":"K Hassan","year":"2019","unstructured":"Hassan K, Kannmacher J, Wohlmuth P et al (2019) Cytosorb adsorption during emergency cardiac operations in patients at high risk of bleeding. Ann Thorac Surg 108:45\u201351. https:\/\/doi.org\/10.1016\/j.athoracsur.2018.12.032","journal-title":"Ann Thorac Surg"},{"key":"740_CR63","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1159\/000489921","volume":"46","author":"D Pomar\u00e8 Montin","year":"2018","unstructured":"Pomar\u00e8 Montin D, Ankawi G, Lorenzin A et al (2018) Biocompatibility and cytotoxic evaluation of new sorbent cartridges for blood hemoperfusion. Blood Purif 46:187\u2013195. https:\/\/doi.org\/10.1159\/000489921","journal-title":"Blood Purif"},{"key":"740_CR64","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1080\/13645706.2022.2104617","volume":"31","author":"A Nierhaus","year":"2022","unstructured":"Nierhaus A, Morales J, Wendt D et al (2022) Comparison of the CytoSorb(\u00ae) 300 mL and Jafron HA380 hemoadsorption devices: an in vitro study. Minim Invasive Ther Allied Technol 31:1058\u20131065. https:\/\/doi.org\/10.1080\/13645706.2022.2104617","journal-title":"Minim Invasive Ther Allied Technol"},{"key":"740_CR65","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1159\/000493523","volume":"47","author":"G Ankawi","year":"2019","unstructured":"Ankawi G, Fan W, Pomar\u00e8 Montin D et al (2019) A new series of sorbent devices for multiple clinical purposes: current evidence and future directions. Blood Purif 47:94\u2013100. https:\/\/doi.org\/10.1159\/000493523","journal-title":"Blood Purif"},{"key":"740_CR66","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1111\/j.1744-9987.2010.00825.x","volume":"14","author":"Z Huang","year":"2010","unstructured":"Huang Z, Wang SR, Su W et al (2010) Removal of humoral mediators and the effect on the survival of septic patients by hemoperfusion with neutral microporous resin column. Ther Apher Dial 14:596\u2013602. https:\/\/doi.org\/10.1111\/j.1744-9987.2010.00825.x","journal-title":"Ther Apher Dial"},{"key":"740_CR67","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1111\/j.1744-9987.2012.01083.x","volume":"17","author":"Z Huang","year":"2013","unstructured":"Huang Z, Wang SR, Yang ZL et al (2013) Effect on extrapulmonary sepsis-induced acute lung injury by hemoperfusion with neutral microporous resin column. Ther Apher Dial 17:454\u2013461. https:\/\/doi.org\/10.1111\/j.1744-9987.2012.01083.x","journal-title":"Ther Apher Dial"},{"key":"740_CR68","doi-asserted-by":"publisher","DOI":"10.1159\/000542469","author":"Y Li","year":"2024","unstructured":"Li Y, Han M, Yang M et al (2024) Hemoperfusion with the HA330\/HA380 cartridge in intensive care settings: a state-of-the-art review. Blood Purif. https:\/\/doi.org\/10.1159\/000542469","journal-title":"Blood Purif"},{"key":"740_CR69","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000514149","volume":"51","author":"Z He","year":"2022","unstructured":"He Z, Lu H, Jian X et al (2022) The efficacy of resin hemoperfusion cartridge on inflammatory responses during adult cardiopulmonary bypass. Blood Purif 51:31\u201337. https:\/\/doi.org\/10.1159\/000514149","journal-title":"Blood Purif"},{"key":"740_CR70","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1159\/000534852","volume":"53","author":"J Wang","year":"2024","unstructured":"Wang J, Chen B, Xie J et al (2024) Effects of blood hemoadsorption therapy with HA-380 in total arch replacement for acute type A aortic dissection: a retrospective observational study. Blood Purif 53:138\u2013150. https:\/\/doi.org\/10.1159\/000534852","journal-title":"Blood Purif"},{"key":"740_CR71","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1177\/2192568220941684","volume":"10","author":"JR Dettori","year":"2020","unstructured":"Dettori JR, Norvell DC (2020) How fragile are the results of a trial? The fragility index. Global Spine J 10:940\u2013942. https:\/\/doi.org\/10.1177\/2192568220941684","journal-title":"Global Spine J"},{"key":"740_CR72","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1159\/000532050","volume":"53","author":"J Ke","year":"2024","unstructured":"Ke J, Wei Y, Chen B (2024) Application of hemoperfusion in the treatment of acute poisoning. Blood Purif 53:49\u201360. https:\/\/doi.org\/10.1159\/000532050","journal-title":"Blood Purif"},{"key":"740_CR73","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1159\/000445991","volume":"42","author":"A Li","year":"2016","unstructured":"Li A, Li W, Hao F et al (2016) Early stage blood purification for paraquat poisoning: a multicenter retrospective study. Blood Purif 42:93\u201399. https:\/\/doi.org\/10.1159\/000445991","journal-title":"Blood Purif"},{"key":"740_CR74","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1159\/000526149","volume":"52","author":"A Lorenzin","year":"2023","unstructured":"Lorenzin A, de Cal M, Marcello M et al (2023) Vancomycin adsorption during in vitro model of hemoperfusion with mini-module of HA380 cartridge. Blood Purif 52:174\u2013182. https:\/\/doi.org\/10.1159\/000526149","journal-title":"Blood Purif"},{"key":"740_CR75","doi-asserted-by":"publisher","DOI":"10.1159\/000534108","author":"T Furukawa","year":"2023","unstructured":"Furukawa T, Lankadeva Y, Baldwin IC et al (2023) Vancomycin and gentamicin removal with the HA380 cartridge during experimental hemoadsorption. Blood Purif. https:\/\/doi.org\/10.1159\/000534108","journal-title":"Blood Purif"},{"key":"740_CR76","doi-asserted-by":"publisher","DOI":"10.1159\/000542332","author":"T Furukawa","year":"2024","unstructured":"Furukawa T, Lankadeva Y, Baldwin I et al (2024) Removal of meropenem and piperacillin during experimental hemoadsorption with the HA380 cartridge. Blood Purif. https:\/\/doi.org\/10.1159\/000542332","journal-title":"Blood Purif"},{"issue":"Suppl 3","key":"740_CR77","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000499520","volume":"47","author":"C Monard","year":"2019","unstructured":"Monard C, Rimmel\u00e9 T, Ronco C (2019) Extracorporeal blood purification therapies for sepsis. Blood Purif 47(Suppl 3):1\u201314. https:\/\/doi.org\/10.1159\/000499520","journal-title":"Blood Purif"},{"issue":"Suppl 3","key":"740_CR78","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000499510","volume":"47","author":"V Schwindenhammer","year":"2019","unstructured":"Schwindenhammer V, Girardot T, Chaulier K et al (2019) oXiris\u00ae use in septic shock: experience of two french centres. Blood Purif 47(Suppl 3):1\u20137. https:\/\/doi.org\/10.1159\/000499510","journal-title":"Blood Purif"},{"key":"740_CR79","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0220444","volume":"14","author":"ME Broman","year":"2019","unstructured":"Broman ME, Hansson F, Vincent JL et al (2019) Endotoxin and cytokine reducing properties of the oXiris membrane in patients with septic shock: a randomized crossover double-blind study. PLoS ONE 14:e0220444. https:\/\/doi.org\/10.1371\/journal.pone.0220444","journal-title":"PLoS ONE"},{"key":"740_CR80","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s13613-023-01224-8","volume":"13","author":"PD Wendel-Garcia","year":"2023","unstructured":"Wendel-Garcia PD, Eberle B, Kleinert E-M et al (2023) Effects of enhanced adsorption haemofiltration versus haemoadsorption in severe, refractory septic shock with high levels of endotoxemia: the ENDoX bicentric, randomized, controlled trial. Ann Intensive Care 13:127. https:\/\/doi.org\/10.1186\/s13613-023-01224-8","journal-title":"Ann Intensive Care"},{"key":"740_CR81","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1186\/s13054-023-04555-x","volume":"27","author":"G Wang","year":"2023","unstructured":"Wang G, He Y, Guo Q et al (2023) Continuous renal replacement therapy with the adsorptive oXiris filter may be associated with the lower 28-day mortality in sepsis: a systematic review and meta-analysis. Crit Care 27:275. https:\/\/doi.org\/10.1186\/s13054-023-04555-x","journal-title":"Crit Care"},{"key":"740_CR82","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1186\/s13054-023-04588-2","volume":"27","author":"X Huang","year":"2023","unstructured":"Huang X, Zhang F, Zhong Y (2023) Comment on: Continuous renal replacement therapy with the adsorptive oXiris filter may be associated with the lower 28-day mortality in sepsis: a systematic review and meta-analysis. Crit Care 27:305. https:\/\/doi.org\/10.1186\/s13054-023-04588-2","journal-title":"Crit Care"},{"key":"740_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrc.2024.154844","volume":"83","author":"LY Siew","year":"2024","unstructured":"Siew LY, Lee ZY, Yunos NM et al (2024) Outcomes of extracorporeal blood purification with oXiris\u00ae membrane in critically ill patients: a systematic review and meta-analysis. J Crit Care 83:154844. https:\/\/doi.org\/10.1016\/j.jcrc.2024.154844","journal-title":"J Crit Care"},{"key":"740_CR84","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1001\/jama.2024.20630","volume":"332","author":"X P\u00e9rez-Fern\u00e1ndez","year":"2024","unstructured":"P\u00e9rez-Fern\u00e1ndez X, Ulsamer A, C\u00e1mara-Rosell M et al (2024) Extracorporeal blood purification and acute kidney injury in cardiac surgery: the SIRAKI02 randomized clinical trial. JAMA 332:1446\u20131454. https:\/\/doi.org\/10.1001\/jama.2024.20630","journal-title":"JAMA"},{"key":"740_CR85","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11226719","author":"Y Li","year":"2022","unstructured":"Li Y, Sun P, Chang K et al (2022) Effect of continuous renal replacement therapy with the oXiris Hemofilter on critically ill patients: a narrative review. J Clin Med. https:\/\/doi.org\/10.3390\/jcm11226719","journal-title":"J Clin Med"},{"key":"740_CR86","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s10047-019-01139-x","volume":"23","author":"D Onichimowski","year":"2020","unstructured":"Onichimowski D, Zi\u00f3\u0142kowski H, Nosek K et al (2020) Comparison of adsorption of selected antibiotics on the filters in continuous renal replacement therapy circuits: in vitro studies. J Artif Organs 23:163\u2013170. https:\/\/doi.org\/10.1007\/s10047-019-01139-x","journal-title":"J Artif Organs"},{"key":"740_CR87","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1159\/000330323","volume":"32","author":"TI Ala-Kokko","year":"2011","unstructured":"Ala-Kokko TI, Laurila J, Koskenkari J (2011) A new endotoxin adsorber in septic shock: observational case series. Blood Purif 32:303\u2013309. https:\/\/doi.org\/10.1159\/000330323","journal-title":"Blood Purif"},{"key":"740_CR88","doi-asserted-by":"publisher","first-page":"783","DOI":"10.4103\/0972-5229.146305","volume":"18","author":"HP Shum","year":"2014","unstructured":"Shum HP, Leung YW, Lam SM et al (2014) Alteco endotoxin hemoadsorption in Gram-negative septic shock patients. Indian J Crit Care Med 18:783\u2013788. https:\/\/doi.org\/10.4103\/0972-5229.146305","journal-title":"Indian J Crit Care Med"},{"key":"740_CR89","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1097\/shk.0000000000001503","volume":"54","author":"M Lipcsey","year":"2020","unstructured":"Lipcsey M, Tenhunen J, Pischke SE et al (2020) Endotoxin removal in septic shock with the Alteco LPS adsorber was safe but showed no benefit compared to placebo in the double-blind randomized controlled trial-the asset study. Shock 54:224\u2013231. https:\/\/doi.org\/10.1097\/shk.0000000000001503","journal-title":"Shock"},{"key":"740_CR90","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1159\/000508647","volume":"50","author":"MT Seffer","year":"2021","unstructured":"Seffer MT, Cottam D, Forni LG et al (2021) Heparin 2.0: a new approach to the infection crisis. Blood Purif 50:28\u201334. https:\/\/doi.org\/10.1159\/000508647","journal-title":"Blood Purif"},{"key":"740_CR91","doi-asserted-by":"publisher","DOI":"10.1097\/cce.0000000000000662","volume":"4","author":"SA Chitty","year":"2022","unstructured":"Chitty SA, Mobbs S, Rifkin BS et al (2022) A multicenter evaluation of the seraph 100 microbind affinity blood filter for the treatment of severe COVID-19. Crit Care Explor 4:e0662. https:\/\/doi.org\/10.1097\/cce.0000000000000662","journal-title":"Crit Care Explor"},{"key":"740_CR92","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1093\/ckj\/sfaa063","volume":"13","author":"JJ Schmidt","year":"2020","unstructured":"Schmidt JJ, Eden G, Seffer MT et al (2020) In vitro elimination of anti-infective drugs by the Seraph(\u00ae) 100 Microbind(\u00ae) affinity blood filter. Clin Kidney J 13:421\u2013424. https:\/\/doi.org\/10.1093\/ckj\/sfaa063","journal-title":"Clin Kidney J"},{"key":"740_CR93","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1186\/s13054-022-04044-7","volume":"26","author":"G Eden","year":"2022","unstructured":"Eden G, Schmidt JJ, B\u00fcttner S et al (2022) Safety and efficacy of the Seraph\u00ae 100 Microbind\u00ae Affinity Blood Filter to remove bacteria from the blood stream: results of the first in human study. Crit Care 26:181. https:\/\/doi.org\/10.1186\/s13054-022-04044-7","journal-title":"Crit Care"},{"key":"740_CR94","doi-asserted-by":"publisher","DOI":"10.1097\/cce.0000000000000180","volume":"2","author":"SW Olson","year":"2020","unstructured":"Olson SW, Oliver JD, Collen J et al (2020) Treatment for severe coronavirus disease 2019 with the seraph-100 microbind affinity blood filter. Crit Care Explor 2:e0180. https:\/\/doi.org\/10.1097\/cce.0000000000000180","journal-title":"Crit Care Explor"},{"key":"740_CR95","doi-asserted-by":"publisher","first-page":"e134","DOI":"10.1055\/s-0041-1727121","volume":"5","author":"A Pape","year":"2021","unstructured":"Pape A, Kielstein JT, Kr\u00fcger T et al (2021) Treatment of a critically ill COVID-19 patient with the seraph 100 microbind affinity filter. TH Open 5:e134\u2013e138. https:\/\/doi.org\/10.1055\/s-0041-1727121","journal-title":"TH Open"},{"key":"740_CR96","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1159\/000517430","volume":"51","author":"BS Rifkin","year":"2022","unstructured":"Rifkin BS, Stewart IJ (2022) Seraph-100 hemoperfusion in SARS-CoV-2-infected patients early in critical illness: a case series. Blood Purif 51:317\u2013320. https:\/\/doi.org\/10.1159\/000517430","journal-title":"Blood Purif"},{"key":"740_CR97","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1093\/ndt\/gfab347","volume":"37","author":"JJ Schmidt","year":"2022","unstructured":"Schmidt JJ, Borchina DN, Van\u2019t Klooster M et al (2022) Interim analysis of the COSA (COVID-19 patients treated with the Seraph\u00ae 100 Microbind\u00ae Affinity filter) registry. Nephrol Dial Transplant 37:673\u2013680. https:\/\/doi.org\/10.1093\/ndt\/gfab347","journal-title":"Nephrol Dial Transplant"},{"key":"740_CR98","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1159\/000490234","volume":"46","author":"G La Manna","year":"2018","unstructured":"La Manna G, Donati G (2018) Coupled plasma filtration adsorption: a multipurpose extracorporeal detoxification therapy. Blood Purif 46:228\u2013238. https:\/\/doi.org\/10.1159\/000490234","journal-title":"Blood Purif"},{"key":"740_CR99","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2013-003536","volume":"4","author":"S Livigni","year":"2014","unstructured":"Livigni S, Bertolini G, Rossi C et al (2014) Efficacy of coupled plasma filtration adsorption (CPFA) in patients with septic shock: a multicenter randomised controlled clinical trial. BMJ Open 4:e003536. https:\/\/doi.org\/10.1136\/bmjopen-2013-003536","journal-title":"BMJ Open"},{"key":"740_CR100","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1007\/s00134-021-06501-3","volume":"47","author":"E Garbero","year":"2021","unstructured":"Garbero E, Livigni S, Ferrari F et al (2021) High dose coupled plasma filtration and adsorption in septic shock patients. Results of the COMPACT-2: a multicentre, adaptive, randomised clinical trial. Intensive Care Med 47:1303\u20131311. https:\/\/doi.org\/10.1007\/s00134-021-06501-3","journal-title":"Intensive Care Med"},{"key":"740_CR101","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1186\/s12879-022-07689-5","volume":"22","author":"Y Li","year":"2022","unstructured":"Li Y, Li H, Guo J et al (2022) Coupled plasma filtration adsorption for the treatment of sepsis or septic shock: a systematic review and meta-analysis. BMC Infect Dis 22:714. https:\/\/doi.org\/10.1186\/s12879-022-07689-5","journal-title":"BMC Infect Dis"},{"key":"740_CR102","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1515\/bmt-2015-0056","volume":"60","author":"G Frodsham","year":"2015","unstructured":"Frodsham G, Pankhurst QA (2015) Biomedical applications of high gradient magnetic separation: progress towards therapeutic haeomofiltration. Biomed Tech (Berl) 60:393\u2013404. https:\/\/doi.org\/10.1515\/bmt-2015-0056","journal-title":"Biomed Tech (Berl)"},{"key":"740_CR103","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12951-015-0110-8","volume":"13","author":"IK Herrmann","year":"2015","unstructured":"Herrmann IK, Schlegel AA, Graf R et al (2015) Magnetic separation-based blood purification: a promising new approach for the removal of disease-causing compounds? J Nanobiotechnol 13:49. https:\/\/doi.org\/10.1186\/s12951-015-0110-8","journal-title":"J Nanobiotechnol"},{"key":"740_CR104","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1002\/cyto.990110203","volume":"11","author":"S Miltenyi","year":"1990","unstructured":"Miltenyi S, M\u00fcller W, Weichel W et al (1990) High gradient magnetic cell separation with MACS. Cytometry 11:231\u2013238. https:\/\/doi.org\/10.1002\/cyto.990110203","journal-title":"Cytometry"},{"key":"740_CR105","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1016\/s0140-6736(21)00676-0","volume":"397","author":"RECOVERY Collaborative Group","year":"2021","unstructured":"RECOVERY Collaborative Group (2021) Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 397:1637\u20131645. https:\/\/doi.org\/10.1016\/s0140-6736(21)00676-0","journal-title":"Lancet"},{"key":"740_CR106","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude SL, Frey N, Shaw PA et al (2014) Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 371:1507\u20131517. https:\/\/doi.org\/10.1056\/NEJMoa1407222","journal-title":"N Engl J Med"},{"key":"740_CR107","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s40262-021-01092-0","volume":"61","author":"E Leung","year":"2022","unstructured":"Leung E, Crass RL, Jorgensen SCJ et al (2022) Pharmacokinetic\/pharmacodynamic considerations of alternate dosing strategies of tocilizumab in COVID-19. Clin Pharmacokinet 61:155\u2013165. https:\/\/doi.org\/10.1007\/s40262-021-01092-0","journal-title":"Clin Pharmacokinet"},{"key":"740_CR108","doi-asserted-by":"publisher","first-page":"14077","DOI":"10.1038\/s41598-024-64379-9","volume":"14","author":"N Waalders","year":"2024","unstructured":"Waalders N, van Lier D, Gerretsen J et al (2024) Preclinical and first-in-human safety studies on a novel magnetism-based haemofiltration method. Sci Rep 14:14077. https:\/\/doi.org\/10.1038\/s41598-024-64379-9","journal-title":"Sci Rep"},{"key":"740_CR109","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s40635-023-00510-w","volume":"11","author":"S David","year":"2023","unstructured":"David S, Russell L, Castro P et al (2023) Research priorities for therapeutic plasma exchange in critically ill patients. Intensive Care Med Exp 11:26. https:\/\/doi.org\/10.1186\/s40635-023-00510-w","journal-title":"Intensive Care Med Exp"},{"key":"740_CR110","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/jca.21705","volume":"34","author":"A Padmanabhan","year":"2019","unstructured":"Padmanabhan A, Connelly-Smith L, Aqui N et al (2019) Guidelines on the use of therapeutic apheresis in clinical practice\u2014evidence-based approach from the writing committee of the American society for apheresis: the eighth special issue. J Clin Apher 34:171\u2013354. https:\/\/doi.org\/10.1002\/jca.21705","journal-title":"J Clin Apher"},{"key":"740_CR111","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.658399","volume":"12","author":"T Weber","year":"2021","unstructured":"Weber T (2021) Anti-AAV antibodies in AAV gene therapy: current challenges and possible solutions. Front Immunol 12:658399. https:\/\/doi.org\/10.3389\/fimmu.2021.658399","journal-title":"Front Immunol"},{"key":"740_CR112","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrc.2023.154360","volume":"78","author":"AH de Nooijer","year":"2023","unstructured":"de Nooijer AH, Pickkers P, Netea MG et al (2023) Inflammatory biomarkers to predict the prognosis of acute bacterial and viral infections. J Crit Care 78:154360. https:\/\/doi.org\/10.1016\/j.jcrc.2023.154360","journal-title":"J Crit Care"},{"key":"740_CR113","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41581-019-0199-3","volume":"16","author":"NL Stanski","year":"2020","unstructured":"Stanski NL, Wong HR (2020) Prognostic and predictive enrichment in sepsis. Nat Rev Nephrol 16:20\u201331. https:\/\/doi.org\/10.1038\/s41581-019-0199-3","journal-title":"Nat Rev Nephrol"},{"key":"740_CR114","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1164\/rccm.201512-2544CP","volume":"194","author":"HC Prescott","year":"2016","unstructured":"Prescott HC, Calfee CS, Thompson BT et al (2016) Toward smarter lumping and smarter splitting: rethinking strategies for sepsis and acute respiratory distress syndrome clinical trial design. Am J Respir Crit Care Med 194:147\u2013155. https:\/\/doi.org\/10.1164\/rccm.201512-2544CP","journal-title":"Am J Respir Crit Care Med"},{"key":"740_CR115","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/s2213-2600(23)00330-2","volume":"12","author":"S Cajander","year":"2024","unstructured":"Cajander S, Kox M, Scicluna BP et al (2024) Profiling the dysregulated immune response in sepsis: overcoming challenges to achieve the goal of precision medicine. Lancet Respir Med 12:305\u2013322. https:\/\/doi.org\/10.1016\/s2213-2600(23)00330-2","journal-title":"Lancet Respir Med"}],"container-title":["Intensive Care Medicine Experimental"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40635-025-00740-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40635-025-00740-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40635-025-00740-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T16:04:05Z","timestamp":1742573045000},"score":1,"resource":{"primary":{"URL":"https:\/\/icm-experimental.springeropen.com\/articles\/10.1186\/s40635-025-00740-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,21]]},"references-count":115,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["740"],"URL":"https:\/\/doi.org\/10.1186\/s40635-025-00740-0","relation":{},"ISSN":["2197-425X"],"issn-type":[{"value":"2197-425X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,21]]},"assertion":[{"value":"28 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors received institutional funding from MediSieve Ltd. to conduct a phase-1 study on the safety of their novel magnetism-based haemofiltration method.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"38"}}